Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome

Background. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of...

Full description

Saved in:
Bibliographic Details
Main Authors: Piotr Rola, Adrian Włodarczak, Szymon Włodarczak, Mateusz Barycki, Marek Szudrowicz, Magdalena Łanocha, Łukasz Furtan, Katarzyna Woźnica, Jan Jakub Kulczycki, Joanna Jaroszewska-Pozorska, Michalina Kędzierska, Adrian Doroszko, Maciej Lesiak
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Journal of Interventional Cardiology
Online Access:http://dx.doi.org/10.1155/2022/5223317
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552748137054208
author Piotr Rola
Adrian Włodarczak
Szymon Włodarczak
Mateusz Barycki
Marek Szudrowicz
Magdalena Łanocha
Łukasz Furtan
Katarzyna Woźnica
Jan Jakub Kulczycki
Joanna Jaroszewska-Pozorska
Michalina Kędzierska
Adrian Doroszko
Maciej Lesiak
author_facet Piotr Rola
Adrian Włodarczak
Szymon Włodarczak
Mateusz Barycki
Marek Szudrowicz
Magdalena Łanocha
Łukasz Furtan
Katarzyna Woźnica
Jan Jakub Kulczycki
Joanna Jaroszewska-Pozorska
Michalina Kędzierska
Adrian Doroszko
Maciej Lesiak
author_sort Piotr Rola
collection DOAJ
description Background. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. Methods. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. Results. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. Conclusion. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.
format Article
id doaj-art-f3e4e0e77aff49aaa2901f86fcea99a5
institution Kabale University
issn 1540-8183
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Journal of Interventional Cardiology
spelling doaj-art-f3e4e0e77aff49aaa2901f86fcea99a52025-02-03T05:58:00ZengWileyJournal of Interventional Cardiology1540-81832022-01-01202210.1155/2022/5223317Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical OutcomePiotr Rola0Adrian Włodarczak1Szymon Włodarczak2Mateusz Barycki3Marek Szudrowicz4Magdalena Łanocha5Łukasz Furtan6Katarzyna Woźnica7Jan Jakub Kulczycki8Joanna Jaroszewska-Pozorska9Michalina Kędzierska10Adrian Doroszko11Maciej Lesiak12Witelon Collegium State UniversityWitelon Collegium State UniversityDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyAdalbert’s HospitalDepartment of CardiologyFaculty of Mathematics and Information ScienceDepartment of CardiologyDepartment of CardiologyFaculty of MedicineClinical Department of Internal and Occupational Diseases1st Department of CardiologyBackground. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. Methods. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. Results. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. Conclusion. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.http://dx.doi.org/10.1155/2022/5223317
spellingShingle Piotr Rola
Adrian Włodarczak
Szymon Włodarczak
Mateusz Barycki
Marek Szudrowicz
Magdalena Łanocha
Łukasz Furtan
Katarzyna Woźnica
Jan Jakub Kulczycki
Joanna Jaroszewska-Pozorska
Michalina Kędzierska
Adrian Doroszko
Maciej Lesiak
Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
Journal of Interventional Cardiology
title Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
title_full Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
title_fullStr Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
title_full_unstemmed Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
title_short Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
title_sort magnesium bioresorbable scaffold brs magmaris vs biodegradable polymer des ultimaster in nste acs population 12 month clinical outcome
url http://dx.doi.org/10.1155/2022/5223317
work_keys_str_mv AT piotrrola magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT adrianwłodarczak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT szymonwłodarczak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT mateuszbarycki magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT marekszudrowicz magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT magdalenałanocha magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT łukaszfurtan magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT katarzynawoznica magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT janjakubkulczycki magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT joannajaroszewskapozorska magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT michalinakedzierska magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT adriandoroszko magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome
AT maciejlesiak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome